Skip to main content
B

BUKWANG PHARMACEUTICAL IND CO.,LTD — Investor Relations & Filings

Ticker · 003000 ISIN · KR7003000007 KO Manufacturing
Open in API
Filings indexed 322 across all filing types
Latest filing 2025-07-22 Earnings Release
Country KR South Korea
Listing KO 003000

About BUKWANG PHARMACEUTICAL IND CO.,LTD

https://www.bukwang.co.kr/en/

Bukwang Pharmaceutical is a research and development-focused company that develops, produces, and sells a range of pharmaceutical and oral hygienic products. The company emphasizes an open innovation strategy, leveraging joint ventures, research collaborations, and strategic investments to build a robust drug pipeline. Its key development areas include treatments for central nervous system disorders like schizophrenia, bipolar depression, and dyskinesia in Parkinson's disease. The pipeline also features oncology candidates, such as a treatment for metastatic prostate cancer. Bukwang Pharmaceutical manufactures various dosage forms, including oral solids and injections, alongside over-the-counter medications.

Recent filings

Filing Released Lang Actions
연결재무제표기준영업(잠정)실적(공정공시)
Earnings Release Classification · 1% confidence The document is a 'Provisional Earnings Release' (연결재무제표기준영업(잠정)실적) for Bukwang Pharmaceutical. It provides key financial highlights (revenue, operating profit, net income) for the second quarter of 2025. This type of filing is a standard initial announcement of quarterly financial results, which fits the definition of an Earnings Release (ER). Q2 2025
2025-07-22 Korean
최대주주등소유주식변동신고서
Major Shareholding Notification Classification · 1% confidence The document is a 'Report of Change in Shareholding by Major Shareholders' (최대주주등소유주식변동신고서) for Bukwang Pharm. It details a significant change in share ownership by OCI Holdings, specifically noting an increase in shares due to the acquisition of new shares. This type of filing, which tracks changes in significant share ownership levels (crossing thresholds or major changes by insiders/major shareholders), falls under the 'Major Shareholding Notification' category.
2025-07-21 Korean
증권발행실적보고서
Share Issue/Capital Change Classification · 1% confidence The document is a '증권발행실적보고서' (Report on the Results of Securities Issuance) filed with the Financial Supervisory Service (FSS) in South Korea. It details the final results of a capital increase (rights offering), including subscription status, allocation, use of proceeds, and changes in shareholding. This is a formal regulatory filing required after the completion of a securities issuance process. It does not fit into categories like '10-K' (Annual Report) or 'ER' (Earnings Release), and it is not a mere announcement of a report (RPA). It is a specific regulatory disclosure regarding capital changes.
2025-07-16 Korean
유상증자또는주식관련사채등의발행결과(자율공시)
Share Issue/Capital Change Classification · 1% confidence The document is an official regulatory filing from a Korean company (Bukwang Pharm) detailing the final results of a capital increase (paid-in capital increase/rights offering). It specifies the number of shares issued, the total amount raised, and the payment date. This falls under the category of share issuance and capital changes.
2025-07-16 Korean
기업설명회(IR)개최(안내공시)
Report Publication Announcement Classification · 1% confidence The document is a short announcement (764 characters) regarding the scheduling of an upcoming Investor Relations (IR) meeting. It provides the date, time, and purpose of the meeting but does not contain the actual presentation materials or financial results. According to the 'Menu vs Meal' rule, an announcement of an upcoming event or report is classified as a Report Publication Announcement (RPA) or a general regulatory filing. Given the specific nature of the announcement regarding an IR event, RPA is the most appropriate classification.
2025-07-16 Korean
유상증자또는주식관련사채등의청약결과(자율공시)
Share Issue/Capital Change Classification · 1% confidence The document is an official announcement regarding the results of a capital increase (paid-in capital increase/rights offering) for Bukwang Pharmaceutical. It details the subscription results, including the number of shares subscribed, subscription rates, and future payment/listing dates. This falls under the category of capital and financing updates, specifically related to share issuance and capital changes.
2025-07-15 Korean

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.